| Pharmaceutical and Human Health |
|
Missouri is home to world-class institutions in pharmaceutical and human health research and product development. These include:
Hospitals that are essential research institutions include:
- Barnes Jewish Hospital, Washington University Medical Center, St. Louis
- St. Louis Children's Hospital, Washington University Medical Center
- Children's Mercy Hospital, Kansas City
- St. Luke's Hospital, Kansas City
Biopharmaceutical development companies include:
- Covidien (formerly Mallinckrodt)
St. Louis, MO
This firm manufactures and markets healthcare products in the areas of respiratory care, imaging, and analgesic pharmaceuticals. In 2005, Mallinckrodt investments developments included a 65,000-square-foot pharmaceutical research and development lab and the purchase of cyclotrons, signifying its long-term commitment to nuclear medicine.
- Pfizer Global Research and Development
St. Louis, MO
Pfizer is the world's largest research-based drug manufacturer and has one of its six global R&D centers in St. Louis, Missouri. Pfizer scientists collaborate with researchers at Washington University School of Medicine in St. Louis.
- Centocor Biologics
St. Louis, MO
A Johnson & Johnson subsidiary, Centocor Biologics is a leader in the field of biomedicines that has already begun to unlock the secrets of the immune system — discoveries that have led to innovative treatments for conditions such as Crohn's disease and rheumatoid arthritis.
- Kereos
St. Louis, MO
Kereos, Inc. develops targeted molecular imaging agents and therapeutics designed to detect and treat cancer and cardiovascular disease earlier and more specifically than currently possible. The specificity and unique capabilities of Kereos' molecular imaging agents enable earlier and more definitive diagnosis of disease. Similarly, Kereos' targeted therapeutics seek out definitive disease biomarkers and carry powerful payloads of proven chemotherapeutics, making them potentially more effective and less toxic in treating disease.
- Orion Genomics
St. Louis, MO
Orion Genomics develops oncology diagnostic products for cancer screening and therapy selection. We leverage our suite of proprietary technologies to find and interpret normal and abnormal epigenetic patterns of DNA methylation, also known as DNA's Second Code.
They are currently identifying epigenetic biomarkers and employing them in the development of novel molecular diagnostic tests to find breast, lung, ovarian, colorectal and other common cancers. Additionally, we are discovering biomarkers that can aid in the selection of best therapies for cancer patients.
- Tripos International
St. Louis, MO
This firm helps pharmaceutical companies and research facilities around the world successfully accelerate the identification and optimization of new compounds that have the potential to become drug products. Headquartered in St. Louis, the company serves more than 1,000 customers spanning over 46 countries.
In addition, Kansas City's Midwest Research Institute (MRI) provides research and development for industry in the areas of national defense, health sciences, agriculture and food safety, engineering, environment, information technology, energy, biological sciences and analytical chemistry.
|
|
|
|
BioMed 21 at Washington University
To extend its leading life sciences research programs Washington University (medical campus pictured above) is pursuing BioMed 21. The program reorganizes the life sciences at Washington University to address the biggest questions about disease: their origins, how they affect us and how we can cure them. BioMed 21 establishes three new research units that span both campuses of Washington University: The Center for Genomics and Human Genetics, the Division of Clinical Sciences and the Center for Biological Imaging. The conceptual nucleus around which these three new units orbit is to build upon the work of the Human Genome Project to rapidly advance the diagnosis and treatment of human illnesses
|
